Later, Schork A. et al. published two prospective observational studies to investigate whether SGLT-2 inhibitors might correct fluid overload in adult kidney transplant recipients (KTRs) (n = 22, follow up 6 months) [32] and in CKD patients (n = 42, follow up 6 months) [33]. This evidence concerns the gene SLC5A2 and chronic kidney disease.